Ticker

CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor Dr. Bradley Pentelute to Deliver Opening Remarks CAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™),…

Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript

Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral markets Company to participate in Virtual Investor Closing Bell event to discuss pathforward today at 4:00 PM ET. Access the event here CAMBRIDGE, Mass.

Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, April 9 th at 4:00 PM ET Register for the event here CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple…

CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance with all other applicable continued listing requirements of The Nasdaq…